224 related articles for article (PubMed ID: 35482445)
1. Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling.
Rethnam M; Tan DQ; Tan SH; Li J; Yokomori R; Li Y; Yang H; Sanda T; Suda T
Blood Adv; 2022 Sep; 6(18):5330-5344. PubMed ID: 35482445
[TBL] [Abstract][Full Text] [Related]
2. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Sakamoto K; Katayama R; Asaka R; Sakata S; Baba S; Nakasone H; Koike S; Tsuyama N; Dobashi A; Sasaki M; Ichinohasama R; Takakuwa E; Yamazaki R; Takizawa J; Maeda T; Narita M; Izutsu K; Kanda Y; Ohshima K; Takeuchi K
Leukemia; 2018 Dec; 32(12):2590-2603. PubMed ID: 29795241
[TBL] [Abstract][Full Text] [Related]
3. METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Ai Y; Liu S; Luo H; Wu S; Wei H; Tang Z; Li X; Lv X; Zou C
J Immunol Res; 2021; 2021():6149558. PubMed ID: 34476262
[TBL] [Abstract][Full Text] [Related]
4. Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.
Dang X; Zhou D; Meng L; Bi L
J Int Med Res; 2021 Feb; 49(2):300060520982667. PubMed ID: 33530792
[TBL] [Abstract][Full Text] [Related]
5. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
6. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm.
Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T
Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861
[TBL] [Abstract][Full Text] [Related]
7. [Enhancer hijacking via disease-specific chromosomal translocation in blastic plasmacytoid dendritic cell neoplasm].
Kubota S
Rinsho Ketsueki; 2020; 61(1):47-51. PubMed ID: 32023603
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review.
Wang Y; Xiao L; Yin L; Zhou L; Deng Y; Deng H
Medicine (Baltimore); 2023 Feb; 102(7):e32904. PubMed ID: 36800625
[TBL] [Abstract][Full Text] [Related]
9. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target.
Sapienza MR; Abate F; Melle F; Orecchioni S; Fuligni F; Etebari M; Tabanelli V; Laginestra MA; Pileri A; Motta G; Rossi M; Agostinelli C; Sabattini E; Pimpinelli N; Truni M; Falini B; Cerroni L; Talarico G; Piccioni R; Amente S; Indio V; Tarantino G; Brundu F; Paulli M; Berti E; Facchetti F; Dellino GI; Bertolini F; Tripodo C; Rabadan R; Pileri SA
Haematologica; 2019 Apr; 104(4):729-737. PubMed ID: 30381297
[TBL] [Abstract][Full Text] [Related]
10. Profiling endogenous, environmental, and infectious disease mutational signatures in blastic plasmacytoid dendritic cell neoplasms.
Small C; Mukerjee S; Jangam D; Gollapudi S; Singh K; Jaye DL; Aung PP; Querfeld C; Yao K; Chisholm KM; Pullarkat S; Wang S; Gru A; Hussaini M; George TI; Ohgami RS
Int J Lab Hematol; 2023 Oct; 45(5):726-734. PubMed ID: 37282364
[TBL] [Abstract][Full Text] [Related]
11. E-Cadherin Expression and Blunted Interferon Response in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Lorenzi L; Lonardi S; Vairo D; Bernardelli A; Tomaselli M; Bugatti M; Licini S; Arisi M; Cerroni L; Tucci A; Vermi W; Giliani SC; Facchetti F
Am J Surg Pathol; 2021 Oct; 45(10):1428-1438. PubMed ID: 34081040
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
13. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm.
Bastidas Torres AN; Cats D; Mei H; Fanoni D; Gliozzo J; Corti L; Paulli M; Vermeer MH; Willemze R; Berti E; Tensen CP
Genes Chromosomes Cancer; 2020 May; 59(5):295-308. PubMed ID: 31846142
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features.
Künstner A; Schwarting J; Witte HM; Xing P; Bernard V; Stölting S; Lohneis P; Janke F; Salehi M; Chen X; Kusch K; Sültmann H; Chteinberg E; Fischer A; Siebert R; von Bubnoff N; Merz H; Busch H; Feller AC; Gebauer N
Leukemia; 2024 May; 38(5):1086-1098. PubMed ID: 38600314
[TBL] [Abstract][Full Text] [Related]
15. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
Cheng W; Yu TT; Tang AP; He Young K; Yu L
Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm.
Nomburg J; Bullman S; Chung SS; Togami K; Walker MA; Griffin GK; Morgan EA; LeBoeuf NR; DeCaprio JA; Meyerson M; Lane AA
Blood Adv; 2020 Mar; 4(6):1006-1011. PubMed ID: 32182365
[TBL] [Abstract][Full Text] [Related]
17. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Khoury JD
Curr Hematol Malig Rep; 2018 Dec; 13(6):477-483. PubMed ID: 30350260
[TBL] [Abstract][Full Text] [Related]
18. Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Pemmaraju N; Gupta V; Thompson MA; Lane AA
Curr Hematol Malig Rep; 2016 Dec; 11(6):462-467. PubMed ID: 27492117
[TBL] [Abstract][Full Text] [Related]
19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
20. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.
Sapienza MR; Pileri S
Hematol Oncol Clin North Am; 2020 Jun; 34(3):511-521. PubMed ID: 32336416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
